This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gabrielson, E. W. Articles by Kuhajda, F. P. Search for Related Content PubMed PubMed Citation Articles by Gabrielson, E. W. Articles by Kuhajda, F. P.

Increased Fatty Acid Synthase is a Therapeutic Target in Mesothelioma¹

Departments of Pathology and Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21224 [E. G., M. P., F. P. K.], and the Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 [J. R. T.]

Many common human cancer tissues express high levels of fatty acid synthase (FAS), the primary enzyme for the synthesis of fatty acids, and the differential expression of FAS between normal and neoplastic tissues has led to the consideration of FAS as a target for anticancer therapy. To investigate the potential of targeting FAS for the treatment of pleural mesothelioma, we first determined whether FAS is overexpressed in human mesothelioma. By immunohistochemistry, we found 22 of 30 human mesothelioma tissue samples tested to express significantly increased levels of FAS compared with normal tissues, including mesothelium. To further explore FAS as a therapeutic target in mesothelioma, we established a nude mouse xenograft model for human mesothelioma using the H-Meso cell line. The i.p. xenografts of this cell line have high levels of FAS expression and fatty acid synthesis pathway activity and grow along mesothelial surfaces in a manner similar to the growth pattern of human mesothelioma. Growth of these tumor xenografts was essentially abolished in mice treated with weekly i.p. injections of C75, a synthetic, small molecule inhibitor of FAS, at levels that resulted in no significant systemic toxicity except for reversible weight loss. These results suggest that FAS may be an effective target for pharmacological therapy in a high proportion of human mesotheliomas.

This article has been cited by other articles:

				S. Aja, L. E. Landree, A. M. Kleman, S. M. Medghalchi, A. Vadlamudi, J. M. McFadden, A. Aplasca, J. Hyun, E. Plummer, K. Daniels, et al. Pharmacological stimulation of brain carnitine palmitoyl-transferase-1 decreases food intake and body weight Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2008; 294(2): R352 - R361. [Abstract] [Full Text] [PDF]

				H. Orita, J. Coulter, C. Lemmon, E. Tully, A. Vadlamudi, S. M. Medghalchi, F. P. Kuhajda, and E. Gabrielson Selective Inhibition of Fatty Acid Synthase for Lung Cancer Treatment Clin. Cancer Res., December 1, 2007; 13(23): 7139 - 7145. [Abstract] [Full Text] [PDF]

				W. Zhou, W. F. Han, L. E. Landree, J. N. Thupari, M. L. Pinn, T. Bililign, E. K. Kim, A. Vadlamudi, S. M. Medghalchi, R. El Meskini, et al. Fatty Acid Synthase Inhibition Activates AMP-Activated Protein Kinase in SKOV3 Human Ovarian Cancer Cells Cancer Res., April 1, 2007; 67(7): 2964 - 2971. [Abstract] [Full Text] [PDF]

				F. P. Kuhajda Fatty Acid synthase and cancer: new application of an old pathway. Cancer Res., June 15, 2006; 66(12): 5977 - 5980. [Abstract] [Full Text] [PDF]

				X. Liu, Y. Shi, V. L. Giranda, and Y. Luo Inhibition of the phosphatidylinositol 3-kinase/Akt pathway sensitizes MDA-MB468 human breast cancer cells to cerulenin-induced apoptosis. Mol. Cancer Ther., March 1, 2006; 5(3): 494 - 501. [Abstract] [Full Text] [PDF]

				R.-C. Jiang, H.-D. Qin, M.-S. Zeng, W. Huang, B.-J. Feng, F. Zhang, H.-K. Chen, W.-H. Jia, L.-Z. Chen, Q.-S. Feng, et al. A Functional Variant in the Transcriptional Regulatory Region of Gene LOC344967 Cosegregates with Disease Phenotype in Familial Nasopharyngeal Carcinoma Cancer Res., January 15, 2006; 66(2): 693 - 700. [Abstract] [Full Text] [PDF]

				S. J. Kridel, F. Axelrod, N. Rozenkrantz, and J. W. Smith Orlistat Is a Novel Inhibitor of Fatty Acid Synthase with Antitumor Activity Cancer Res., March 15, 2004; 64(6): 2070 - 2075. [Abstract] [Full Text] [PDF]

				W. Zhou, P. J. Simpson, J. M. McFadden, C. A. Townsend, S. M. Medghalchi, A. Vadlamudi, M. L. Pinn, G. V. Ronnett, and F. P. Kuhajda Fatty Acid Synthase Inhibition Triggers Apoptosis during S Phase in Human Cancer Cells Cancer Res., November 1, 2003; 63(21): 7330 - 7337. [Abstract] [Full Text] [PDF]

				F. D. Camassei, R. Cozza, A. Acquaviva, A. Jenkner, L. Rava, R. Gareri, A. Donfrancesco, C. Bosman, P. Vadala, T. Hadjistilianou, et al. Expression of the Lipogenic Enzyme Fatty Acid Synthase (FAS) in Retinoblastoma and Its Correlation with Tumor Aggressiveness Invest. Ophthalmol. Vis. Sci., June 1, 2003; 44(6): 2399 - 2403. [Abstract] [Full Text] [PDF]

				E.-K. Kim, I. Miller, L. E. Landree, F. F. Borisy-Rudin, P. Brown, T. Tihan, C. A. Townsend, L. A. Witters, T. H. Moran, F. P. Kuhajda, et al. Expression of FAS within hypothalamic neurons: a model for decreased food intake after C75 treatment Am J Physiol Endocrinol Metab, November 1, 2002; 283(5): E867 - E879. [Abstract] [Full Text] [PDF]